BioRegen Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
200
- Stock Symbol
-
920201
- Share Price
-
$3.15
- (As of Friday Closing)
BioRegen General Information
Description
BioRegen Biomedical Changzhou Co Ltd is engaged in the research, development, production and sales of biomedical materials and other products.
Contact Information
Website
www.bioregenmed.comCorporate Office
- Block B, Kangsite Industrial Park
- No. 117 Xueye Road, Xinbei District
- Changzhou, Jiangsu 213125
- China
Corporate Office
- Block B, Kangsite Industrial Park
- No. 117 Xueye Road, Xinbei District
- Changzhou, Jiangsu 213125
- China
BioRegen Stock Performance
As of 20-Nov-2026, BioRegen’s stock price is $3.15. Its current market cap is $215M with 68.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.15 | $3.37 | $3.14 - $14.45 | $215M | 68.2M | 2.44M | $0.20 |
BioRegen Financials Summary
As of 30-Sep-2026, BioRegen has a trailing 12-month revenue of $47.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 428,262 | |||
| Revenue | 47,771 | 39,474 | 32,225 | 28,012 |
| EBITDA | 13,132 | 8,937 | 8,885 | |
| Net Income | 11,926 | 10,616 | 7,290 | 7,078 |
| Total Assets | 84,563 | 54,287 | 41,112 | 34,424 |
| Total Debt | 2,562 | 1,167 | 1,130 | 1,426 |
BioRegen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioRegen Patents
BioRegen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025112235-A1 | Encapsulated hyaluronic acid gel composition, method for preparing same, and use thereof | Inactive | 28-Nov-2023 | ||
| WO-2024222313-A1 | Method for preparing sulfhydrylated natural polysaccharide derivative | Inactive | 24-Apr-2023 | ||
| WO-2021077681-A1 | Hyaluronic acid gel composition for water optoinjection, and preparation method therefor | Inactive | 23-Oct-2019 | ||
| WO-2021077683-A1 | Hyaluronic acid gel for hyaluronic acid injection and use method for hyaluronic acid gel | Inactive | 23-Oct-2019 | ||
| AU-2020348245-A1 | Disulfide bond-linked hyaluronic acid gel for preventing tissue adhesion after abdominal or pelvic cavity surgery and preparation method therefor | Active | 21-Sep-2019 | A61L31/042 |
BioRegen Signals
BioRegen FAQs
-
When was BioRegen founded?
BioRegen was founded in 2008.
-
Where is BioRegen headquartered?
BioRegen is headquartered in Changzhou, China.
-
What is the size of BioRegen?
BioRegen has 200 total employees.
-
What industry is BioRegen in?
BioRegen’s primary industry is Pharmaceuticals.
-
Is BioRegen a private or public company?
BioRegen is a Public company.
-
What is BioRegen’s stock symbol?
The ticker symbol for BioRegen is 920201.
-
What is the current stock price of BioRegen?
As of 20-Nov-2026 the stock price of BioRegen is $3.15.
-
What is the current market cap of BioRegen?
The current market capitalization of BioRegen is $215M.
-
What is BioRegen’s current revenue?
The trailing twelve month revenue for BioRegen is $47.8M.
-
What is BioRegen’s annual earnings per share (EPS)?
BioRegen’s EPS for 12 months was $0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process